HIV-1 gp120 mini V3 loop for broadly neutralizing antibody elicitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccines face challenges in eliciting broadly neutralizing antibodies due to the dense glycan shield on the viral surface, which shields conserved protein epitopes, making it difficult for antibodies to recognize and neutralize diverse HIV strains effectively.
Innovation Solution
A truncated HIV-1 gp120 mini V3 loop, specifically designed to include carbohydrate attachment sites at N295, N301, and N332, is used to elicit broadly neutralizing antibodies by reducing flexibility and enhancing glycan recognition, allowing for the development of immunogens that can bind potent antibodies like PGT 128.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If full-length V3 loop is used in immunogens, then natural conformation and glycan presentation are maintained, but flexibility is excessive and crystallization with antibodies is difficult
Solution Approach 1:
The V3 loop is segmented into a mini V3 loop containing only residues 295-304 and 321-332, which includes the base region with carbohydrate attachment sites (N295, N301, N332) but excludes the flexible tip region (residues 305-320). This segmentation maintains the essential glycan presentation while reducing flexibility to enable crystallization with antibodies.
2Reliability
If full-length V3 loop is used in immunogens, then complete immunogenicity is achieved, but type-specific and non-neutralizing antibodies are elicited that reduce vaccine effectiveness
Solution Approach 1:
The flexible tip region of the V3 loop (residues 305-320) is extracted and removed from the immunogen. This region is responsible for eliciting type-specific and non-neutralizing antibodies. By taking out this harmful portion while retaining the base region with conserved glycan epitopes, the mini V3 loop directs the immune response toward broadly neutralizing antibodies.
3Object-affected harmful factors
If dense glycan shield is present on viral surface, then viral protection is enhanced, but antibody recognition of conserved protein epitopes is blocked
Solution Approach 1:
The mini V3 loop acts as an intermediary structure that presents carbohydrate moieties (glycans) in a controlled manner. By isolating and presenting specific glycan epitopes (at N295, N301, N332) in a truncated context, the immunogen mediates antibody recognition of glycan structures without the protective interference of the full viral glycan shield, enabling development of antibodies that can penetrate viral glycans.
Data Source
AI summary
The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies.